Axitinib (INLYTA)
Kinase Inhibitor class · 1 generic manufacturer · 2 ANDAs filed at FDA.
$682.5M in CY2024 Part D spend38K claims · 8K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Axitinib used for?
Axitinib is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Axitinib?
Yes. 2 ANDAs filed at FDA, 1 generic manufacturers currently shipping.
How much does my plan pay for Axitinib?
NADAC pricing data not currently available for this drug.
Is Axitinib on the FDA shortage list?
No. Axitinib is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.